BioMarin Buying Alesta Therapeutics For Up To $490M
Jones Day-advised BioMarin Pharmaceutical Inc. said Tuesday it has agreed to acquire Alesta Therapeutics for $275 million upfront and up to another $215 million tied to the development and regulatory progress...To view the full article, register now.
Already a subscriber? Click here to view full article